Feature | Stents Bioresorbable | September 08, 2017| Dave Fornell

Abbott Will End Sales of Absorb Bioresorbable Stent

Low sales cited as reason for discontinuing commercial sales of the Absorb

Abbott will end sales of the Absorb bioresorbable stent scaffold, pulling it off the market September 14, 2017.

September 8, 2017 — Abbott Vascular has announced it will end commercial sales of its Absorb bioresorbable vascular scaffold as of Sept. 14, 2017. The company said low sales of the bioabsorbable stent led to the decision to stop offering the product.  

Sales of Absorb will end in all countries, according to Abbott. The company plans to continue the ongoing Absorb clinical trials to assess long-term outcomes after the scaffold has dissolved. Abbott said trial centers can continue to use their existing Absorb inventory, but as of Sept. 14, Abbott will not continue to supply the product. The trials will continue to follow already enrolled patients, but there will not be any new patients enrolled.  

“Due to low commercial sales, Abbott will stop selling the first-generation bioresorbable Absorb coronary stent,” Abbott stated on its website product section for the Absorb. “We pioneered bioresorbable technology because we believe it offers patients the possibility of life without permanent metallic implants, and we will continue work on a next generation bioresorbable device."

"First-generation products often go through iterations as experience is gained using them," said Abbott spokesman Jonathon Hamilton. "Absorb is a highly innovative ground-breaking device, and we're incorporating learnings into a second-generation product." 

The company said its metallic Xience drug-eluting stent (DES) will continue to be the cornerstone of Abbott’s vascular stent portfolio. The vendor also stated it will focus efforts on a next generation metallic DES, the Xience Sierra, which is supposed to offer improved deliverability and expanded sizes. 

The Absorb stent was originally hailed as a major advance forward in coronary stent technology when it received regulatory approval for commercial sales in Europe in 2011 and the United States in July 2016. However, as use of the stent expanded and new trial data revealed, it was found the scaffold has several limitations compared to metallic stents. These include delivery issues due to the thicker struts, stent recoil, the limited ability to over-expand without breaking struts, the need for very precise sizing, and poor outcomes if the Absorb is used in coronary vessels 2.5 mm or smaller. Perhaps the biggest barrier to wider adoption was the much higher price tag for Absorb over traditional metallic DES. 

While the Absorb also has some advantages over metallic stents, these were not enough to persuade interventional cardiologists to increase their usage.

Read the full article “Questions Remain on Future of Bioresorbable Stents article.” 

Watch a VIDEO with Gregg Stone, M.D., "Poor Outcomes for Bioresorbable Stents in Small Coronary Arteries."

These issues were brought up in discussions at numerous sessions that involved bioresorbable stents at the 2017 American College of Cardiology (ACC) meeting in March. Experienced users of the Absorb in trials said the stent can be used effectively, but that the new technology has a learning curve and it is not simply a replacement for metallic stents interventionalists have been using for two decades. Stephen Ellis, M.D., professor of medicine and director of interventional cardiology at Cleveland Clinic, was key in these discussions at ACC with his presentation of the late-breaking two year outcomes of the ABSORB III trial of Absorb vs. Xience. Watch a VIDEO interview with Ellis, "Bioresorbable Stent Comparable to Xience at Two Years, With Concerns," or read the article on the ABSORB III results.  

 

Related Content on the Absorb Bioresorbable Scaffold:

VIDEO: What Went Wrong With the Absorb Stent? - interview with Ajay Kirtane, M.D., at TCT 2017

Current State of Bioresorbable Stent Technology (Update article from January 2018)

Tempering the Bioresorbable Stent Euphoria Following FDA Clearance of the Absorb

VIDEO: Bioresorbable Stent Failure Modes, Technique, Patient Selection and Future Development — a discussion with Juan Granada, M.D., executive director and chief scientific officer of the Cardiovascular Research Foundation's Skirball Center for Innovation.

Bioresorbable Stent Comparable to Xience at Two Year, But With Adverse Trends

FDA Approves First Totally Bioresorbable Stent

VIDEO: Key Bioresorbable Stent Technology Presented at TCT 2015 — an interview with Dean Kereiakes, M.D., medical director of The Christ Hospital Heart and Vascular Center, and a lead investigator for both the ABSORB and SYNERGY stent trials.

Bioresorbable Stents Are the Way of the Future

The Future of Stent Development Depends on Bigger Improvements in Outcomes

 

Related Content

TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
htisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...